Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups
This clinical trial aims to subclass mental health conditions within diabetes using digital twins to enable precision mental health tracking…
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: Therapy and Tech Study [NA]
A trial update noting a therapy and technology study sponsored by UC Irvine for generalized anxiety disorder and major depressive disorder; …
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: ACT for Individuals With MNCD and Their Care Partners [Phase 1]
Phase 1 clinical trial update on Acceptance and Commitment Therapy (ACT) for individuals with MNCD and their care partners, including Depres…
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: Evaluation of Teen Connection Project for Trans and Gender Minority Youth [NA]
Completed clinical trial by the University of Michigan evaluating the Teen Connection Project for transgender and gender minority youth, foc…
-
CLINICAL_TRIALS trial_result · 2025-10-29Clinical Trial Update: Researching Resiliency in Stressful Experiences (RISE) Program for Men Leaving Incarceration [NA]
This ClinicalTrials.gov entry reports the completed results of the RISE program, a resilience intervention for men leaving incarceration, ev…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-27Clinical Trial Update: A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) [Phase 2]
Phase 2 clinical trial update for CYB004, a N,N-dimethyltryptamine analog, in Generalized Anxiety Disorder; the study is currently active bu…
-
FDA approval · 2025-10-17FDA Approved: BUCAPSOL — Supplemental Application (PANGEA PHARMACEUTICALS, LLC)
The FDA approved a supplemental application for BUCAPSOL (buspirone hydrochloride) from PANGEA PHARMACEUTICALS, LLC, under an ANDA supplemen…
-
CLINICAL_TRIALS trial_result · 2025-10-16Clinical Trial Update: Cancer Within a Pandemic: A Telemental Health Intervention [NA]
A Wake Forest University Health Sciences trial evaluating a telemental health intervention for cancer patients during the pandemic was termi…
-
CLINICAL_TRIALS trial_result · 2025-10-10Clinical Trial Update: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial evaluating the efficacy and safety of SEP-363856 in adults with generalized anxiety disorder has completed.
-
FDA approval · 2025-10-09FDA Approved: ESCITALOPRAM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Escitalopram oxalate (escitalopram) from Sun Pharmaceutical Industries, authorizing its marketin…
-
FDA approval · 2025-10-06FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for buspirone hydrochloride from Rising Pharma Holdings, Inc., allowing a change to an existing gene…
-
FDA approval · 2025-10-01FDA Approved: PREGABALIN — Supplemental Application (Creekwood Pharmaceuticals LLC)
The FDA approved a supplemental application for pregabalin from Creekwood Pharmaceuticals LLC under ANDA213423.
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: Hybrid Type 1 Randomized Pilot Trial of a Peer-led Family and Social Strengthening Group Intervention for Refugee Families [NA]
This clinical trial update describes a hybrid Type 1 randomized pilot evaluating a peer-led family and social strengthening group interventi…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: The Effect of Patient Preference for Treatment Model in Internet Delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder [NA]
Karolinska Institutet is recruiting a study to evaluate how patient preference for treatment model influences outcomes in internet-delivered…
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder [Phase 2]
Phase 2 trial ENX-102 as monotherapy for generalized anxiety disorder has completed.
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Treating Young Adult Generalized Anxiety Disorder With Text-Message Delivered Cognitive Behavioral Therapy [NA]
Completed clinical trial evaluating text-message delivered cognitive behavioral therapy for Generalized Anxiety Disorder in young adults.
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Optimization of Imagery Rescripting Research Using Generative Artificial Intelligence [NA]
Clinical trial update describing the optimization of imagery rescripting research using generative AI for generalized anxiety disorder, with…
-
FDA approval · 2025-09-24FDA Approved: PAROXETINE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approves Alembic Pharmaceuticals Inc. Paroxetine Original Application for a generic paroxetine product.
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Internet-Based Cognitive Behavioral Therapy With Treatment as Usual for Generalized Anxiety Disorder and Major Depressive Disorder in Taiwan (ICBT-TW) [NA]
A clinical trial in Taiwan evaluating internet-based cognitive behavioral therapy in addition to usual care for generalized anxiety disorder…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Physical Exercise Augmented CBT for GAD [NA]
This clinical trial update describes a study testing physical exercise–augmented cognitive-behavioral therapy for generalized anxiety disord…
-
FDA approval · 2025-09-17FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Epic Pharma, LLC)
The FDA approved a supplemental application for venlafaxine hydrochloride from Epic Pharma, LLC under an ANDA.
-
FDA approval · 2025-09-17FDA Approved: PREGABALIN — Supplemental Application (MARKSANS PHARMA LIMITED)
The FDA approved a supplemental application for pregabalin from Marksans Pharma Limited, resulting in approval of a generic pregabalin produ…
-
CLINICAL_TRIALS trial_result · 2025-09-17Clinical Trial Update: A Dose-Response Safety Study of ENX-102 in Patients With GAD [Phase 2]
This document reports the completion of a Phase 2 dose-response safety study of ENX-102 in patients with Generalized Anxiety Disorder.
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: Navigated cTBS for the Treatment of Generalized Anxiety Disorder [NA]
A clinical trial is evaluating navigated cTBS for Generalized Anxiety Disorder; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Massage for GAD: Neuroimaging and Clinical Correlates of Response [NA]
This clinical trial investigates the effects of massage therapy on generalized anxiety disorder and uses neuroimaging to study response, wit…